StreetInsider.com News Articles

Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant

Wed, 11 Mar 2026 08:00:00 -0400

First Cochlear Implant Company to Announce Completed Enrollment of a U.S. Pivotal Clinical Trial for a Fully Implanted Cochlear Implant seeking FDA Approval

White Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56^th and final patient, Envoy Medical is the first cochlear implant company to achieve full enrollment of a U.S. pivotal clinical trial to evaluate a fully

Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant

Wed, 11 Mar 2026 08:00:00 -0400

First Cochlear Implant Company to Announce Completed Enrollment of a U.S. Pivotal Clinical Trial for a Fully Implanted Cochlear Implant seeking FDA Approval

Form 8-K Envoy Medical, Inc. For: Feb 23

Fri, 27 Feb 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260227/26076623.html

Form 8-K Envoy Medical, Inc. For: Feb 23

Fri, 27 Feb 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260227/26076623.html

Envoy Medical regains Nasdaq compliance after meeting listing requirements

Tue, 24 Feb 2026 08:02:14 -0400

Envoy Medical Inc. (NASDAQ: COCH) announced it received written notification from Nasdaq confirming compliance with Listing Rule 5550(b)(2) through permitted alternatives under the rule.

The hearing health company had received a notice from Nasdaq on February 25, 2025, indicating non-compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities of $35 million. Envoy Medical subsequently implemented strategic financing initiatives and strengthened its balance sheet to regain compliance.

The company stated it believes it has a plan to maintain compliance and expects to remain listed on the Nasdaq Capital Market under the symbol "COCH."

Envoy Medical develops fully implanted

Envoy Medical Regains Compliance with Nasdaq Listing Requirement

Tue, 24 Feb 2026 08:00:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b).

As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of

Envoy Medical Regains Compliance with Nasdaq Listing Requirement

Tue, 24 Feb 2026 08:00:00 -0400

Envoy Medical receives three new patents for hearing implant technology

Mon, 23 Feb 2026 08:05:31 -0400

Envoy Medical Inc. (NASDAQ: COCH) announced the issuance of three new patents for its fully implanted hearing solutions, with one patent granted in the United States and two in Hong Kong.

The U.S. Patent and Trademark Office granted U.S. Patent No. 12,544,564 on February 10, 2026, titled "Cochlear Implant System with Improved Input Signal-to-Noise Ratio." The patent covers cochlear implant systems with signal processors designed to filter input signals and provide electrical stimulation.

The Hong Kong Patent Office issued two complementary patents. Hong Kong Patent No. HK40102155, titled "Combination Hearing Aid and Cochlear Implant System," relates to systems that can detect and

Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space

Mon, 23 Feb 2026 08:00:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry.

"We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical. "As the industry realizes the

Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space

Mon, 23 Feb 2026 08:00:00 -0400

Envoy Medical raises $30 million, nears clinical trial completion

Thu, 19 Feb 2026 08:02:26 -0400

Envoy Medical Inc. (NASDAQ: COCH) closed a $30 million public offering with potential for an additional $48 million through milestone-linked warrants, the hearing health company announced.

The financing was led by Nantahala Capital and longtime shareholder Glen Taylor. Other participants included Broadfin Holdings, existing shareholders, board members and management. The company stated the full $78 million potential funding could support operations through initial commercialization into 2029.

Envoy Medical reported progress in its pivotal clinical trial for the investigational Acclaim cochlear implant. The trial has enrolled 47 of the required 56 participants, with nine remaining participants identified and scheduled for surgery. The company

Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial

Thu, 19 Feb 2026 08:00:00 -0400

Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor

Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization

Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25^th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanter

White Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health

Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial

Thu, 19 Feb 2026 08:00:00 -0400

Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor

Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization

Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25^th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanter

White Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Patel Mona Chetan

Tue, 17 Feb 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260217/26014593.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Patel Mona Chetan

Tue, 17 Feb 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260217/26014593.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Potashnick Robert

Tue, 17 Feb 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260217/26014541.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Potashnick Robert

Tue, 17 Feb 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260217/26014541.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Kantor Susan

Tue, 17 Feb 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260217/26014478.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Kantor Susan

Tue, 17 Feb 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260217/26014478.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Lucas Brent T.

Tue, 17 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260217/26014403.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: Lucas Brent T.

Tue, 17 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260217/26014403.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: BRYNELSEN CHARLES

Tue, 17 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260217/26014411.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: BRYNELSEN CHARLES

Tue, 17 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260217/26014411.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: TAYLOR GLEN A

Tue, 17 Feb 2026 13:35:00 -0400

si-local-file:///var/storage/secattach/20260217/26010738.html

Form 4 Envoy Medical, Inc. For: Feb 12 Filed by: TAYLOR GLEN A

Tue, 17 Feb 2026 13:35:00 -0400

si-local-file:///var/storage/secattach/20260217/26010738.html